Carbogen announces $110m investment in Switzerland and France

The facilities, located in Switzerland and France, will be phased in over the next four years

Carbogen Amcis has announced two expansion projects that will increase its manufacturing capacity.

In Switzerland, the project will be initiated in 2021 with construction of an API manufacturing facility at its Hunzenschwil site. The unit is planned to be operational by summer 2024.

“The facility is designed to provide space for Carbogen to grow over the next 10 years with the initial phase comprising of 12 new vessels (from 630 litres to 4000 litres) and associated filtration and drying capabilities,” said Stephan Fritschi, VP of Operations. “We have an impressive pipeline, and now our customers can benefit from more diverse offerings.”

The French site will be able to supply both clinical batches up to phase III and small-scale for commercial. There will be two automated lines

In addition to the Swiss API manufacturing facility, additional investments are planned with a dedicated budget to improve some of the existing technologies and to increase the capacity of current Swiss sites, such as adding chromatography equipment, reactors in production and additional laboratories.

In France, 7 km from an existing site in Riom, construction will begin in January 2021 on a facility dedicated to custom development and manufacturing of parenteral drug products.

The facility will allow handling complex formulations, including range of of APIs from biologics to any kind of highly potent compound.

Pascal Villemagne, VP of Sales and Marketing said: “Our new facility in Riom will not only enable us to support more customers, but will also give them access to innovative fill and finish technologies.”

The French site will be able to supply both clinical batches up to phase III and small-scale for commercial. There will be two automated lines: the first one for both liquid filling plus lyophilization and the second one dedicated to liquid forms. Development and analytical laboratories will be incorporated to support customer projects. Operations will commence during Q1 of 2023.

“Our objective is ambitious, nevertheless, we are taking a responsible approach to our growth in order to give the company and our employees a sustainable future. As an established leader in the pharmaceutical outsourcing industry for the past 40 years and with strong relationships with our customers, our company is ready to take this next step in capability and capacity. We are embarking on the expansions in order to secure Carbogen Amcis’s position,” said Mark Griffiths, CEO of Carbogen.

Companies